Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Discussion at XV International AIDS Conference Focuses on How to Provide Antiretroviral Drugs to Developing World

July 13, 2004

Delegates and speakers at the XV International AIDS Conference in Bangkok, Thailand, on Tuesday called for broader accessibility to antiretroviral treatment, as access to HIV/AIDS medications continues to elude millions around the world. Jim Kim, who heads the World Health Organization project tasked with scaling up treatment -- the 3 by 5 Initiative -- expressed shame over the six million people who have died of AIDS since the conference last met two years ago. "By these measures of human life, the ones that really matter, we have failed and we have failed miserably to do enough in the precious time that has passed since Barcelona," he said.

Protestors agreed, arguing that the availability of cheap generic drugs would remove the largest barrier to access. But first, advocates said that brand-name pharmaceutical companies must forgo their patents for certain drugs in developing countries. Hank McKinnell, CEO of Pfizer, argued that forgoing patents will dry-up innovation. "People living with HIV are going to need a steady stream of new therapies as this virus mutates and currently available treatments fail patients. If 'Access for All' is all that we do in the first sense, access for those needing medicines today, then the theme of future IAS conferences will surely be 'Why are treatments failing patients?'"

However, maintaining research and development should not keep needed medications from people who cannot afford them, according to Walden Bello from the University of the Philippines. "R&D for HIV drugs and other essential medicines is no longer efficient within a corporate context. Big pharma is more interested in protecting its 20% margin, provided by monopolistic pricing based on patents, than in providing drugs to people with little purchasing power."

Advertisement
Neither side denies there is a need to provide these medications; they just disagree on the best way to get them to the millions of people who need them (Jill Braden, Kaiser Daily HIV/AIDS Report, 7/13).

Video highlights of the day's events are available online.

Back to other news for July 13, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report.
 
See Also
More HIV News

 

Advertisement